Maze Therapeutics, Inc. (MAZE) Institutional Ownership

Ownership Summary

Maze Therapeutics, Inc. (NASDAQ:MAZE) showed up in the 13F filings of 137 institutional investors as of December 2025.

• These investors held 104.9% of outstanding shares in December 2025, up from 93.8% in September 2025.
• Their total shares held in MAZE increased 13.6% from the prior quarter, while the number of investors in Maze Therapeutics stayed flat year over year.
• Of these 137 funds, 98 grew their exposure to Maze Therapeutics, 21 cut back, and 18 maintained positions.
• Institutional investors collectively held 48.02Mn shares in Maze Therapeutics as of December 2025, up by 5.75Mn shares quarter on quarter, and with no net change year over year.
• As of December 31, 2025, the biggest holder of Maze Therapeutics is Janus Henderson Group Plc at 5.72Mn shares, representing 12.49% of shares outstanding.
• The most significant purchases of MAZE for the quarter ending December 2025 came from Paradigm Biocapital Advisors LP (2.74Mn), Janus Henderson Group Plc (2.58Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.44Mn), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.18Mn), Cormorant Asset Management, LP (750.0K).
• The biggest sellers of Maze Therapeutics for the quarter ending December 2025 included Deep Track Capital, LP (768.88K), MARSHALL WACE, LLP (536.83K), Woodline Partners LP (385.0K), Foresite Capital Management IV, LLC (365.76K), ADAR1 Capital Management, LLC (308.97K).
• According to Business Quant data, leading holders of MAZE for December 2025 are Janus Henderson Group Plc (5.72Mn), Frazier Life Sciences Management, L.P. (4.57Mn), TRV GP IV, LLC (4.47Mn), ARCH Venture Management, LLC (4.12Mn), Deep Track Capital, LP (3.48Mn), Paradigm Biocapital Advisors LP (2.74Mn), BlackRock, Inc. (2.57Mn), a16z Capital Management, L.L.C. (1.7Mn), Venrock Adviser, LLC (1.6Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.44Mn).